Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver

Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Ross Laybutt, Sof Andrikopoulous, Ian E. Alexander, Mathew J. Watt, Peter W. Angus, Chandana B. Herath – 22 December 2021 – Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is frequently associated with type 2 diabetes. However, there is no specific medical therapy to treat this condition. Angiotensin‐converting enzyme 2 (ACE2) of the protective renin angiotensin system generates the antifibrotic peptide angiotensin‐(1‐7) from profibrotic angiotensin II peptide.

Subscribe to